Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fasting during chemo: a new way to boost treatment?

NCT ID NCT05327608

Recruiting now Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether time-restricted eating (TRE) — a 16:8 fasting schedule — is feasible for patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy. Participants will follow TRE for 16 weeks while receiving chemo, and researchers will measure how many patients can stick to the fasting plan at least 70% of the time. The study also looks at whether TRE affects body weight, waist size, and the rate of complete tumor response to chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Time-restricted eating (intermittent fasting) — a 16:8 schedule of 16 hours fasting and 8 hours eating
What this could lead to
If time-restricted eating is feasible and beneficial, it could become a supportive strategy to help breast cancer patients tolerate chemotherapy and potentially improve treatment response.
What could go wrong
This is a small phase 2 trial, so results may not be conclusive. Adherence to fasting can be challenging, and the study does not yet prove that fasting improves cancer outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer ductal breast carcinoma in situ Her2-receptor negative breast cancer hormone receptor-positive breast cancer invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE I BREAST CANCER AJCC V8 ANATOMIC STAGE II BREAST CANCER AJCC V8 ANATOMIC STAGE III BREAST CANCER AJCC V8 BREAST DUCTAL CARCINOMA IN SITU HER2-NEGATIVE BREAST CARCINOMA HORMONE RECEPTOR POSITIVE BREAST CARCINOMA INVASIVE BREAST CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.